What is OccamzRazor?
OccamzRazor is at the forefront of neurodegenerative disease research, specializing in innovative drug discovery through digital science. The company meticulously analyzes and comprehends the complexities of brain aging, with a particular emphasis on developing effective treatment solutions for conditions such as Parkinson's disease. Their target markets include the pharmaceutical and medical sectors, as well as researchers dedicated to advancing neuroscience. OccamzRazor's cutting-edge approach aims to make substantial contributions to the future of patient care and neurological therapies.
How much funding has OccamzRazor raised?
OccamzRazor has raised a total of $6.1M across 1 funding round:
Other Financing Round
$6.1M
Other Financing Round (2022): $6.1M with participation from Valor Equity Partners, re.Mind Capital, Lauder Partners, and Jeff Dean
Key Investors in OccamzRazor
Valor Equity Partners
Valor Equity Partners, established in 2001 and headquartered in Chicago, Illinois, provides financial services focused on investment activities, particularly for businesses.
re.Mind Capital
re.Mind Capital is an investment entity that has participated in OccamzRazor's funding round, contributing to the company's strategic growth.
Lauder Partners
Lauder Partners, LLC is an investment firm that backs innovative companies, particularly in the technology sector, with a preference for opportunities near Silicon Valley.
What's next for OccamzRazor?
The substantial enterprise-level funding positions OccamzRazor for accelerated growth and expanded research initiatives. With a focus on addressing critical unmet needs in neurodegenerative disease treatment, the company is poised to leverage this capital for further development of its digital science platform and drug discovery pipeline. Future strategic investments will likely focus on clinical trial progression and market penetration, solidifying OccamzRazor's role as a key innovator in the neuroscience landscape.
See full OccamzRazor company page
